Enhancing Mesothelioma Prognosis
Early detection improves the prognosis of mesothelioma. As a result, research funds have been committed to exploring methods to diagnose the disease at an earlier stage. The Mesomark® assay, for example, is a simple blood test that detects a biomarker secreted into the circulation by mesothelioma cells.
This biomarker, known as Soluble Mesothelin-Related Peptides (SMRP), can be high for many years before symptoms manifest and the disease is diagnosed.
Scientists have also concentrated on developing new medications and treatments to provide hope for a better prognosis for mesothelioma patients. Over the last decade, new chemotherapeutic medications and treatments that deliver more targeted radiation to the tumour have enhanced the life expectancy of patients with mesothelioma.
Furthermore, experimental treatments including as immunotherapy, gene therapy, and photodynamic therapy have shown some success in the treatment of mesothelioma.
If you have been diagnosed with mesothelioma and have concerns about the different mesothelioma treatment options available at Penn Medicine, please contact a Penn Medicine mesothelioma Patient Navigator now.
How Long Do Patients With Mesothelioma Live Without Treatment?
Without treatment, people diagnosed with the earliest stage of mesothelioma, known as stage 1a, live an average of two years. Without treatment, those diagnosed with stage 4 mesothelioma live an average of six to eight months.
Patients who have surgery for pleural mesothelioma stages 1 or 2 may live for more than three years. Half of the peritoneal mesothelioma patients who have surgery and hot chemotherapy live for more than five years.
Several other prognostic markers, including as cancer’s tumour grade, the patient’s overall health, age and gender, and whether the patient chooses palliative treatment to reduce symptoms and increase their quality of life, can also have a significant impact on survival.
According to a 2019 study published in Thoracic Surgery, almost one-third of persons with malignant mesothelioma tumours prefer not to take any sort of anti-cancer treatment.